Clinical trials: Non-communicable Diseases
RSV Infection, Drug Drug Interaction (DDI)
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
The primary aim of the study is to assess the effect of itraconazole, carbamazepine, quinidine, and fluconazole individually on the pharmacokinetics and safety of EDP-323 in healthy adult participants.
- Trial name
- NCT06847464
- Testing
- EDP-323, Itraconazole, carbamazepine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Warts, Warts Hand
CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts
This prospective, multicenter, single-blinded, randomized comparison study is designed to compare the safety and effectiveness of the CellFX System to Cryosurgery for the clearance of cutaneous non-genital common warts on all…
- Conditions
- Warts, Warts Hand, Verruca
- Trial name
- NCT04738734
- Testing
- CellFX System Device, Cryosurgery Liquid Nitrogen Sprayer
- Where
- 10 sites in United States
- Volunteers
- 150 people
- Sponsor
- Pulse Biosciences, Inc.
Respiratory Syncytial Virus Infection, Premature Birth
Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children
100 Russian children of 2 years of age and less in high-risk populations (preterm, and/or with heart and lung problems) will receive palivizumab (Synagis) 15 mg/kg intramuscularly as prophylaxis to severe respiratory syncytial…
- Conditions
- Respiratory Syncytial Virus Infection, Premature Birth, Bronchopulmonary Dysplasia, Congenital Heart Disease
- Trial name
- NCT01006629
- Testing
- palivizumab
- Where
- 19 sites in Russia
- Volunteers
- 100 people
- Sponsor
- Abbott
COVID-19 Respiratory Infection, Viral Pneumonia
Study of the Use of the Drug Ingaron in Patients With COVID-19
Interferon gamma is a powerful endogenous regulatory cytokine that activates the antiviral immune response, while it also has its own antiviral activity.
- Trial name
- NCT05386459
- Testing
- Interferon Gamma
- Where
- Russia
- Volunteers
- 36 people
- Sponsor
- SPP Pharmaclon Ltd.
Hepatitis C, Hepatitis C, Chronic
Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin
Chronic hepatitis C infection is one of the leading causes of chronic liver disease in the United States. Approximately one-third of patients with hepatitis C infection develop cirrhosis of the liver, which can lead to liver…
- Trial name
- NCT00039962
- Testing
- thymalfasin (thymosin alpha 1), PEGinterferon alfa-2a
- Where
- 56 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- SciClone Pharmaceuticals
Recurrent Condyloma, Nonrecurrent Condyloma
Recurrent and Nonrecurrent Condyloma Treatment
Treatment is considered successful if the difference in the response in the reduction of the affected area is above 30% for any of the doses compared to placebo Patients will be randomised to 1 of 3 treatment arms 1. Placebo 2.
- Trial name
- NCT01639638
- Testing
- PROAPOPTOTIC PEPTIDE CIGB 300
- Where
- Argentina
- Volunteers
- 132 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Uveitis
Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.
- Trial name
- INSURE (NCT01095250)
- Testing
- AIN457
- Where
- 36 sites in United States, Canada and 11 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis C, Chronic
Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients
The purpose of this study is to assess the ability of SB-497115-GR to raise platelet counts in thrombocytopenic patients with hepatitis C virus (HCV) infection (platelet count <80,000 /μL, suggestive of compensated cirrhosis) to…
- Trial name
- NCT01636778
- Testing
- SB-497115-GR
- Where
- 16 sites in Japan
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Influenza
Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over
This observer blind study is designed to compare the immune response of GSK Biologicals' influenza vaccine GSK576389A when administered using various presentations in adults aged 65 years and older.
- Trial name
- NCT00532298
- Testing
- GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season], GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season], Fluarix [NH 2006/07 season]
- Where
- 6 sites in Denmark, Estonia and 1 more
- Volunteers
- 1,596 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Non-infectious Anterior Uveitis
A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis
This is a randomized, multi-center, investigator masked, comparator controlled study. The purpose of this study is to determine the efficacy and safety of NS2 in patients with non-infectious acute anterior uveitis.
- Trial name
- NCT02406209
- Testing
- NS2, Prednisolone acetate ophthalmic suspension (1%)
- Where
- 15 sites in United States
- Volunteers
- 45 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Infection
Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS
This study was aimed evaluate long-term immunity response by neutralizing antibody test of adults in high risk population of HFRS .
- Trial name
- NCT02360514
- Testing
- Hantavax injection
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Non-Infectious Anterior Uveitis
Oftac Eye Drops (0.05% Tacrolimus Ophthalmic Emulsion) for the Treatment of Active Non-infectious Anterior Uveitis
The goal of this clinical trial is to assess the safety and tolerability of Oftac in active non-infectious anterior uveitis patients. The main questions it aims to answer are: 1.
- Trial name
- NCT07869953
- Testing
- Oftac: 0.05% tacrolimus ophthalmic emulsion
- Where
- 7 sites in Israel
- Volunteers
- 18 people
- Sponsor
- BioNanoSim Ltd.
HIV Infections
A Study of MKC-442 in Combination With Other Anti-HIV Drugs
The purpose of this study is to see if it is safe and effective to give MKC-442 plus stavudine (d4T) plus didanosine (ddI) plus hydroxyurea.
- Trial name
- NCT00002412
- Testing
- Emivirine, Hydroxyurea, Stavudine
- Where
- United States
- Sponsor
- Triangle Pharmaceuticals
Hepatitis C, Chronic
A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)
This open-label, non-comparative study will assess the safety and tolerability of individualized combination therapy with Copegus (ribavirin) and Pegasys (peginterferon alfa-2a) in patients with chronic hepatitis C.
- Trial name
- NCT01296971
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Selgantolimod (Formerly GS-9688) in Viremic Adult Participants With Chronic Hepatitis B (CHB) Who Are Not Currently on Treatment
The primary objectives of this study are to evaluate the safety and tolerability of multiple oral doses of selgantolimod and to evaluate the antiviral activity of selgantolimod in adult participants with chronic hepatitis B (CHB)…
- Trial name
- NCT03615066
- Testing
- Selgantolimod, TAF
- Where
- 10 sites in Canada, South Korea and 1 more
- Volunteers
- 67 people
- Sponsor
- Gilead Sciences
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
The AudibleHealth Dx is a diagnostic software as a medical device (Dx SaMD) consisting of an ensemble of software subroutines that interacts with a proprietary database of Signal Data Signatures (SDS), using Artificial…
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, COVID-19 Pandemic
- Trial name
- NCT05364268
- Testing
- Diagnostic Test: Diagnostic Software as Medical Device
- Where
- United States
- Volunteers
- 514 people, healthy volunteers welcome
- Sponsor
- AudibleHealth AI, Inc.
Uveitis
Assessment of Safety , Clinical Efficacy With QLETLI in Non-infectious Uveitis (UV)
This is a multicenter, prospective, post-marketing clinical study with a total of 60 uveitis (UV) subjects planned to be enrolled.
- Trial name
- NCT05180526
- Testing
- QLETLI
- Where
- 7 sites in China
- Volunteers
- 60 people
- Sponsor
- Bio-Thera Solutions
HPV Infection
Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females
The purpose of this study is to evaluate the immunogenicity and safety of three consecutive lots of bivalent HPV (Type 16,18) vaccine (Pichia pastoris) in healthy female subjects aged 9 - 30 years, and demonstrate the…
- Trial name
- NCT04965350
- Testing
- Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)
- Where
- China
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Shanghai Zerun Biotechnology Co.,Ltd
Hepatitis C
A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients
This is a proof of concept study, designed to look at the safety and antiviral activity of LCQ908 in hepatitis C infected patients.
- Trial name
- NCT01387958
- Testing
- LCQ908
- Where
- 2 sites in New Zealand
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
HCV Infection
Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice
This study will collect and evaluate information on the safety and efficacy of Sovaldi-based regimens in routine clinical practice in Mexico.
- Trial name
- NCT02783976
- Testing
- Sovaldi
- Where
- 6 sites in Mexico
- Volunteers
- 25 people
- Sponsor
- Gilead Sciences